2018
Individual and joint effect of postdiagnostic metformin and statin use on prostate cancer mortality among patients with high-risk prostate cancer.
Lu-Yao G, E J, Lin Y, Rebbeck T, Lu S, Kelly W, D'Amico A, Stein M, Zhang L, Kim I, Demissie K, Ferrari A, Tan X. Individual and joint effect of postdiagnostic metformin and statin use on prostate cancer mortality among patients with high-risk prostate cancer. Journal Of Clinical Oncology 2018, 36: 202-202. DOI: 10.1200/jco.2018.36.6_suppl.202.Peer-Reviewed Original ResearchHigh-risk CaPCAP mortalityM1 diseaseHazard ratioTime-varying Cox proportional hazards modelsHigh-risk prostate cancerCox proportional hazards modelHigh-risk CaP.Post-diagnostic useProstate cancer mortalityUse of statinsPopulation-based studyEffect of statinsProstate cancer metastasisCause of deathProportional hazards modelMetformin useSEER databaseRandomized trialsCancer mortalityProstate cancerMedicare filesStatinsHazards modelMetformin
2017
Outcomes for men under 65 with high-risk prostate cancer with Medicaid versus private insurance.
Mahal A, Mahal B, Nguyen P, Yu J. Outcomes for men under 65 with high-risk prostate cancer with Medicaid versus private insurance. Journal Of Clinical Oncology 2017, 35: 198-198. DOI: 10.1200/jco.2017.35.6_suppl.198.Peer-Reviewed Original ResearchProstate cancer-specific mortalityHigh-risk prostate cancerProstate cancerTreatment of high-risk prostate cancerInsurance statusCompeting-risks regression modelsHigh-risk CaPPrivately insured menGray's competing-risks regression modelHigh-risk diseaseCancer-specific mortalityEnd Results ProgramMultivariate logistic regressionMetastatic diseaseNon-black menResults ProgramPrivate insuranceInsured menAfrican American menLogistic regressionMetSOutcomesCancerMenMore-than-additive effect
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply